The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence

• Main Authors: Antonino Capizzi (Author), Michela Silvestri (Author), Andrea Orsi (Author), Renato Cutrera (Author), Giovanni A. Rossi (Author), Oliviero Sacco (Author)
• Format: Book
• Published: BMC, 2017-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Following the most recent modification by the American Academy of Pediatrics, based on American studies on RSV epidemiology, the Italian Drug Agency (AIFA) decided to limit the total financial coverage of the palivizumab prescription by the National Health Service only to the < 29 wGA gr...